NPAT down 21.0% but a NZ$49.2m operating cash swing is the bigger issue

The driver is a NZ$27.8m operating working-capital absorption, which sits at the upper edge of Annolyse's historical baseline (mean NZ$8.1m, with one prior period showing a NZ$72.6m build and two showing releases). Inventories climbed 16.4% to NZ$197.3m.

Revenue fell 6.5% to NZ$500.9m, against a historical mean growth rate of 8.1% and a range of -1.2% to 22.4%, so the top line is below normal. PBT declined 21.1% to NZ$20.9m and NPAT declined 21.0% to NZ$14.3m, both within historical ranges. Gross borrowings rose 15.4% to NZ$126.1m. The interim dividend was held at 15cps.

• OCF moved from roughly break-even to a NZ$50.7m outflow, funded through a NZ$16.8m increase in gross borrowings. The build is at the upper edge of the historical range rather than off the chart, but the year-on-year delta is what is squeezing the balance sheet now. This matters because the dividend was held while operating cash was negative; the half is being underwritten by debt, not internal cash generation.

• Margins are holding at the top of the historical range, so the earnings decline is volume-driven rather than margin compression. PBT margin of 4.2% is above the four-period mean of 3.2% and at the upper edge of the 2.2%–4.9% range; NPAT margin of 2.9% is similarly above its 2.1% mean. Management retains pricing or mix discipline despite a 6.5% revenue contraction, which reads as a softer demand environment more than a competitive problem.

• Returns and leverage are both moving the wrong way together. ROE fell from 6.7% to 4.7%, while net debt rose to roughly NZ$109.9m (from NZ$95.7m) and gross borrowings now sit at NZ$126.1m. Equity has grown 11.8%, so the ratios are not alarming yet, but the direction matters because the borrowing increase is financing inventory, not earning assets.

The shape context is the FY22 split, in which HY22 contributed 72.9% of full-year NPAT and 59.4% of revenue, implying H1-weighted earnings historically. If that pattern repeats, the current NZ$14.3m NPAT implies a full-year figure in the high teens against FY22's NZ$24.8m. That comparison should be treated cautiously because the HY22 base was described as a record, and the shape may not generalise.

The release does not break out forward order book, supply commitments, or expected inventory unwind, so the second-half cash recovery from inventory clearance is the key open variable rather than anything in this disclosure.

Margin strength sits at the upper edge of the historical range and the effective tax rate (28.1% vs 28.4% prior) is broadly stable, so the 21.0% NPAT decline is a clean read on weaker volumes against a record prior-year comparable rather than an accounting effect. Tax did not distort the result.

Cash quality is the weak point. Operating cash flow was negative for the second consecutive interim period, but this year's outflow is roughly 34 times larger, and the inventory-led working-capital absorption of NZ$27.8m is NZ$19.7m above the historical mean. The payout ratio against NPAT was 34.3% (versus 27.1% prior), which still looks modest, but covers an NPAT that was not converted to cash this half. The result is balance-sheet-assisted in the sense that debt funded inventory build, dividend and operations together; durability depends on the inventory clearing in H2.

This briefing cannot assess management's underlying view on demand, supply allocation, or the expected timing of inventory unwind because no forward commentary or guidance was supplied in the release.